Congenital Hyperinsulinism (CHI) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Congenital hyperinsulinism (CHI) is an uncommon genetic disorder marked by excessive and uncontrolled insulin release from the pancreas's β-cells, resulting in severe and persistent hypoglycemia. Up to 14 known genetic factors contribute to CHI, while in some cases, CHI is a part of a broader syndrome. The primary cause of severe CHI is typically a mutation in the ABCC8 and KCNJ11 genes. In rarer instances, genetic anomalies affecting the regulation of insulin secretion from pancreatic beta cells can lead to CHI. Since CHI is present from birth, symptoms typically manifest within the first few days of life. Hypoglycemic symptoms encompass floppiness, trembling, feeding difficulties, and drowsiness stemming from low blood sugar levels. Seizures can also occur due to low blood sugar. Loss of consciousness and potential brain injury are possible outcomes without prompt correction of the child's blood glucose levels. Medical treatment using diazoxide or octreotide is employed for preoperative management and in cases where surgery is unsuccessful.

·       The estimated incidence of CHI is approximately 1 in every 30,000 individuals. However, it is notably more prevalent in communities where consanguineous marriages are common, with a potential occurrence as frequent as one in every 2,500 children.

 

Thelansis’s “Congenital Hyperinsulinism (CHI) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Congenital Hyperinsulinism (CHI) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Congenital Hyperinsulinism (CHI) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Congenital Hyperinsulinism (CHI) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Congenital Hyperinsulinism (CHI) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Congenital Hyperinsulinism (CHI), Congenital Hyperinsulinism (CHI) market outlook, Congenital Hyperinsulinism (CHI) competitive landscape, Congenital Hyperinsulinism (CHI) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)